骨形成促进剂用于骨质疏松症治疗  

Osteoanabolic agents in the treatment of osteoporosis

作　　者：郑文彬 李梅 ZHENG Wen-bin;LI Mei(Department of Endocrinology,Peking Union Medical College Hospital,Peking Union Medical College&Chinese Academy of Medical Sciences,Key Laboratory of Endocrinology,National Commission of Health,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院内分泌科,国家卫生健康委员会内分泌重点实验室,北京100730

出　　处：《中华骨质疏松和骨矿盐疾病杂志》2019年第5期525-531,共7页Chinese Journal Of Osteoporosis And Bone Mineral Research

基　　金：国家自然科学基金面上项目(81570802,81873668);国家重点研发计划(2016YFC0901501);中国医学科学院医学与健康科技创新工程项目(2016-I2M-3-003)。

摘　　要：骨质疏松症是以骨强度下降、骨折风险增加为特征的全身性骨骼疾病。骨转换失衡是骨质疏松症的主要病理生理机制,因而促进骨形成及抑制骨吸收成为骨质疏松症治疗的主要方向。近年来,骨形成促进剂的研究取得长足进展,能够增加骨密度、改善骨微结构、提升骨强度、降低骨折风险,在骨质疏松治疗领域具有重要的应用前景。本文对甲状旁腺素相关制剂、硬骨抑素及Dickkopf-1的单克隆抗体等多种骨形成促进剂的作用机制、临床治疗效果及安全性等研究进展进行综述,以助于骨质疏松症的临床治疗选择。Osteoporosis is a systemic skeletal disease characterized by decreased bone strength and increased fracture risk.The main pathophysiological mechanism of osteoporosis is imbalance of bone turnover.Promoting bone formation and inhibiting bone resorption has become the mainstay of anti-osteoporotic treatment.Recently,great progress has been made in osteoanabolic agents,which can increase bone mineral density,improve bone microstructure,increase bone strength,and reduce fracture risk.Osteoanabolic agents will have important applications in the treatment of osteoporosis.We review the progress of the mechanism,clinical efficacy and safety of osteoanabolic agents,such as agents of parathyroid hormone,monoclonal antibody to sclerostin or Dickkopf-1.

关 键 词：骨质疏松症 骨形成促进剂 WNT通路 单克隆抗体 

分 类 号：R681[医药卫生—骨科学]